Back to search results

Researching Beta-Glucan and Exercise for Immune Function

This study is looking into whether a dietary supplement called beta-glucan (a type of fiber from mushrooms) can improve your immune system's ability to fight cancer cells. It also wants to see if combining beta-glucan with exercise has extra benefits. You could be eligible if you are a healthy adult between 18 and 45 years old, physically fit, and do not have certain health conditions like a very high BMI, diabetes, or autoimmune diseases. Researchers will compare beta-glucan to a placebo (an inactive substance) to see if it helps immune cells recognize cancer cells. The study aims to enroll 60 participants, but its current recruitment status is unclear.

Study design
This is a randomized, placebo-controlled study with 60 planned participants. It is an interventional study, meaning participants will receive a specific treatment.
What's involved
You will take beta-glucan or a placebo daily for 4 weeks. You will also visit the laboratory for three exercise tests and provide blood samples.
Compensation
Not stated in the trial record.
Follow-up
Your cellular cytotoxicity will be measured at baseline, at the end of treatment (four weeks), and eight weeks after a washout phase.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07305259

Researching Economical Adjuvants to Cancer Therapy

Recruiting
EARLY_PHASE1Ages 18–45InterventionalBasic science
Florida State University
~60 participants
Updated 2025-12-26 on ClinicalTrials.gov
What's tested:Beta-glucanPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cellular Cytotoxicity Assessed With Flow Cytometry
Measured over At baseline, the end of treatment at four weeks, and at eight weeks after a washout phase.

Conditions

Healthy Participants

Explore related trials

Healthy Participants

Where it's being run

1 sites across 1 states
Florida1

Who to contact

Kyle A Smith, PhD, RD
[email protected]
850-644-1016
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Physically fit enough to engage in maximal exercise.

Exclusion

BMI \> 40 kg/m2
Stage 2 hypertension (140/90 mmHg)
Type I or II diabetes
Autoimmune diseases
Overt cardiovascular, respiratory, or neurological disease (e.g., previous heart attack, pacemaker, heart failure, asthma)
Hormone replacement therapy (e.g., androgens, estrogens)
Daily medication usage that may affect immune function (e.g., beta blockers, NSAIDs, corticosteroids, allergy medications)
Current antibiotic use
Heavy alcohol usage (\>2 drinks per day)
Tobacco use within the last 6 months
Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers)
Self-reported pregnancy
Prisoners

What this trial measures

  • Cellular Cytotoxicity Assessed With Flow CytometryAt baseline, the end of treatment at four weeks, and at eight weeks after a washout phase.

    The ability of participant peripheral blood mononuclear cells (PBMCs) to kill target cancers cells in vitro. PBMCs will be co-cultured with cancer cells for four hours, and the number of cancer cells killed over time will be quantified with flow cytometry (e.g., CD71+ labeled cancer cells with compromised cell membranes).